NCT05119569FenebrutinibRMSCOVID-19UTIpharyngitisMSOLE
…on’s tyrosine kinase inhibitor. In the Phase II FENopta study ( NCT05119569), participants received Fenebrutinib 200mg orally BID or placeb…
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT05119569 ×
NCT05119569
This funder is selected. Its supporting articles are shown below.